Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
12:47pm, Tuesday, 10'th Jun 2025
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using Y
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
06:51pm, Monday, 09'th Jun 2025
The latest trading day saw Bristol Myers Squibb (BMY) settling at $49, representing a +1.22% change from its previous close.
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
10:56am, Monday, 09'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
06:35am, Sunday, 08'th Jun 2025
How would you like to get paid every quarter (and sometimes every month) to own a stock? That's exactly what happens when you invest in dividend stocks.
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
10:21am, Friday, 06'th Jun 2025
Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter's investigational bispecific ant
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
07:00am, Friday, 06'th Jun 2025
Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327
5 All-Star High-Yield Dividend Stocks Every Boomer Should Own
04:10pm, Wednesday, 04'th Jun 2025
While reaching retirement age can be both a blessing and a curse, relying on the U.S. government to provide for your needs is not the best idea. The full retirement age is 66 if you were born from 194
Bristol Myers Collaborates With BNTX for Oncology Candidate
01:16pm, Tuesday, 03'rd Jun 2025
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
06:46pm, Monday, 02'nd Jun 2025
Bristol Myers Squibb (BMY) closed the most recent trading day at $48.79, moving +1.06% from the previous trading session.
Bristol Myers CEO explains why he's spending billions on BioNTech deal
03:50pm, Monday, 02'nd Jun 2025
Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth ann
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
02:51pm, Monday, 02'nd Jun 2025
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
12:22pm, Monday, 02'nd Jun 2025
Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The comp
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
11:08am, Monday, 02'nd Jun 2025
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
08:46am, Monday, 02'nd Jun 2025
Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
07:42am, Monday, 02'nd Jun 2025
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
